• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Corium touts study results for once-daily ADHD capsule

October 14, 2021 By Sean Whooley

CoriumCorium (NSDQ:CORI) today announced clinical data demonstrating the strong performance of its once-daily ADHD capsule.

Boston-based Corium’s Azstarys oral capsule for treating ADHD symptoms (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) received FDA approval in March as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six years and older.

Results from a phase 3 controlled classroom clinical trial, set to be presented tomorrow during the American Psychiatric Nurses Association (APNA) 35th Annual Conference, showed that Azstarys significantly reduced ADHD symptoms in children ages 6-12 years old.

Investigators randomized 150 children to receive Azstarys or placebo during a seven-day, double-blind treatment period that followed a three-week dose-optimization phase, according to a news release.

The primary efficacy endpoint was the mean change in the Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale – Combined (SKAMP-C) during the classroom day. Results found that the SKAMP-C was significantly lower (indicating improvement) with Azstarys compared to placebo (mean change of -4.87 vs. 0.54, respectively).

Azstarys also demonstrated improvements in ADHD symptoms measured by a secondary efficacy endpoint, the Weekly Rating of Evening and Morning Behavior – Revised (WREMB-R). The mean change from baseline in WREMB-R scores for Azstarys vs. placebo were -11.7 vs. -7.2.

The trial observed no serious adverse events, deaths or overdoses in the study. The majority of treatment-affected adverse events were graded as mild or moderate, with such events proving similar to those reported for approved methylphenidate drugs.

“The clinical data from the classroom study demonstrate that the first medicine to combine the innovative d-MPH prodrug with d-MPH can safely and effectively improve ADHD symptoms in children,” President of the Center for Psychiatry and Behavioral Medicine and investigator in the Azstarys clinical trial Dr. Ann Childress said in the release. “Azstarys gives parents and clinicians another option when seeking an ADHD therapy for children.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Corium

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS